The Ketogenic Diet in Children with Epilepsy: A Focus on Parental Stress and Family Compliance
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Design
2.2. Participants
2.3. Parenting Stress Index—Short Form
- -
- Parental Distress (PD), which represents the stress related to the parenting role. This subscale measures the level of stress that the parent is experiencing in his role, which is understood to be derived from personal factors directly related to that role (e.g., responsibility in managing the different aspects related to the child’s pathology; personal life limitations related to child management).
- -
- Dysfunctional Parent–Child Interaction Scale (P-CDI), which assesses the level of stress related to parent–child interaction. This subscale measures the level of stress that occurs when the parent perceives the child as not responding to their expectations, and interactions with the child do not reinforce them as a parent (e.g., my child fails to do as well as I expected; I have the feeling that my efforts are not much appreciated).
- -
- Difficult Child Scale (DC) which assesses the stress related to characteristics of the child. This subscale measures the level of stress related to the child’s peculiar characteristics which render them difficult to manage and which often originate in their temperament, including defiant and disobedient behaviors (e.g., crying, irritability, problematic behaviors, problem of sleep, problem of feeding).
2.4. Statistical Analysis
3. Results
3.1. Participants
3.2. Comparison of Parental Stress at Baseline after 6 and 12 Months on the Ketogenic Diet
4. Discussion
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Kossoff, E.H.; Zupec-Kania, B.A.; Auvin, S.; Ballaban-Gil, K.R.; Christina Bergqvist, A.G.; Blackford, R.; Buchhalter, J.R.; Caraballo, R.H.; Cross, J.H.; Dahlin, M.G.; et al. Optimal clinical management of children receiving dietary therapies for epilepsy: Updated recommendations of the International Ketogenic Diet Study Group. Epilepsia Open. 2018, 3, 175–192. [Google Scholar] [CrossRef] [PubMed]
- Coppola, G.; Verrotti, A.; Ammendola, E.; Operto, F.F.; Corte, R.D.; Signoriello, G.; Pascotto, A. Ketogenic diet for the treatment of catastrophic epileptic encephalopathies in childhood. Eur. J. Paediatr. Neurol. 2010, 14, 229–234. [Google Scholar] [CrossRef] [PubMed]
- D’Andrea Meira, I.; Romão, T.T.; Pires do Prado, H.J.; Krüger, L.T.; Pires, M.E.P.; da Conceição, P.O. Ketogenic Diet and Epilepsy: What We Know So Far. Front. Neurosci. 2019, 13, 5. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hong, A.M.; Turner, Z.; Hamdy, R.F.; Kossoff, E.H. Infantile spasms treated with the ketogenic diet: Prospective single-center experience in 104 consecutive infants. Epilepsia 2010, 51, 1403–1407. [Google Scholar] [CrossRef]
- Oguni, H.; Fukuyama, Y.; Tanaka, T.; Hayashi, K.; Funatsuka, M.; Sakauchi, M.; Shirakawa, S.; Osawa, M. Myoclonic-astatic epilepsy of early childhood—Clinical and EEG analysis of myoclonic-astatic seizures, and discussions on the nosology of the syndrome. Brain Dev. 2001, 23, 757–764. [Google Scholar] [CrossRef]
- Coppola, G.; Klepper, J.; Ammendola, E.; Fiorillo, M.; della Corte, R.; Capano, G.; Pascotto, A. The effects of the ketogenic diet in refractory partial seizures with reference to tuberous sclerosis. Eur. J. Paediatr. Neurol. 2006, 10, 148–151. [Google Scholar] [CrossRef]
- Veggiotti, P.; Burlina, A.; Coppola, G.; Cusmai, R.; De Giorgis, V.; Guerrini, R.; Tagliabue, A.; Dalla Bernardina, B. The ketogenic diet for Dravet syndrome and other epileptic encephalopathies: An Italian consensus. Epilepsia 2011, 2, 83–89. [Google Scholar] [CrossRef]
- Ray, A.; Wyllie, E. Treatment options and paradigms in childhood temporal lobe epilepsy. Expert Rev. Neurother. 2005, 5, 785–801. [Google Scholar] [CrossRef]
- Prudencio, M.B.; de Lima, P.A.; Murakami, D.K.; Sampaio, L.P.B.; Damasceno, N.R.T. Micronutrient supplementation needs more attention in patients with refractory epilepsy under ketogenic diet treatment. Nutrition 2021, 86, 111158. [Google Scholar] [CrossRef]
- Kossoff, E.H.; Dorward, J.L. The modified Atkins diet. Epilepsia 2008, 8, 37–41. [Google Scholar] [CrossRef]
- Sondhi, V.; Agarwala, A.; Pandey, R.M.; Chakrabarty, B.; Jauhari, P.; Lodha, R.; Toteja, G.S.; Sharma, S.; Paul, V.K.; Kossoff, E.; et al. Efficacy of Ketogenic Diet, Modified Atkins Diet, and Low Glycemic Index Therapy Diet Among Children with Drug-Resistant Epilepsy: A Randomized Clinical Trial. JAMA Pediatr. 2020, 174, 944–951. [Google Scholar] [CrossRef]
- Wells, J.; Swaminathan, A.; Paseka, J.; Hanson, C. Efficacy and Safety of a Ketogenic Diet in Children and Adolescents with Refractory Epilepsy-A Review. Nutrients 2020, 12, 1809. [Google Scholar] [CrossRef] [PubMed]
- Operto, F.F.; Matricardi, S.; Pastorino, G.M.G.; Verrotti, A.; Coppola, G. The Ketogenic Diet for the Treatment of Mood Disorders in Comorbidity with Epilepsy in Children and Adolescents. Front. Pharmacol. 2020, 11, 578396. [Google Scholar] [CrossRef]
- Coppola, G.; Verrotti, A.; D’Aniello, A.; Arcieri, S.; Operto, F.F.; Della Corte, R.; Ammendola, E.; Pascotto, A. Valproic acid and phenobarbital blood levels during the first month of treatment with the ketogenic diet. Acta Neurol. Scand. 2010, 122, 303–307. [Google Scholar] [CrossRef] [PubMed]
- Sarlo, G.L.; Holton, K.F. Caregiver perspectives on dietary therapies for epilepsy. Epilepsy Res. 2021, 178, 106803. [Google Scholar] [CrossRef] [PubMed]
- Pulsifer, M.B.; Gordon, J.M.; Brandt, J.; Vining, E.P.; Freeman, J.M. Effects of ketogenic diet on development and behavior: Preliminary report of a prospective study. Dev. Med. Child. Neurol. 2001, 43, 301–306. [Google Scholar] [CrossRef] [PubMed]
- Zuberi, S.M.; Wirrell, E.; Yozawitz, E.; Wilmshurst, J.M.; Specchio, N.; Riney, K.; Pressler, R.; Auvin, S.; Samia, P.; Hirsch, E.; et al. ILAE classification and definition of epilepsy syndromes with onset in neonates and infants: Position statement by the ILAE Task Force on Nosology and Definitions. Epilepsia 2022, 63, 1349–1397. [Google Scholar] [CrossRef]
- Guarino, A.; Laghi, F.; Serantoni, G.; Di Blasio, P.; Camisasca, E. Parenting Stress Index, 4th ed.; (PSI-4); Giunti, O.S.: Firenze, Italy, 2016. [Google Scholar]
- Operto, F.F.; Pastorino, G.M.G.; Scuoppo, C.; Padovano, C.; Vivenzio, V.; Pistola, I.; Belfiore, G.; Rinaldi, R.; de Simone, V.; Coppola, G. Adaptive Behavior, Emotional/Behavioral Problems and Parental Stress in Children with Autism Spectrum Disorder. Front. Neurosci. 2021, 15, 751465. [Google Scholar] [CrossRef]
- Operto, F.F.; Smirni, D.; Scuoppo, C.; Padovano, C.; Vivenzio, V.; Quatrosi, G.; Carotenuto, M.; Precenzano, F.; Pastorino, G.M.G. Neuropsychological Profile, Emotional/Behavioral Problems, and Parental Stress in Children with Neurodevelopmental Disorders. Brain Sci. 2021, 11, 584. [Google Scholar] [CrossRef]
- Operto, F.F.; Pastorino, G.M.G.; Amadori, E.; Mazza, R.; Bernardo, P.; Campanozzi, S.; Margari, L.; Coppola, G. Cognitive Profile, Emotional-Behavioral Features, and Parental Stress in Boys With 47, XYY Syndrome. CognBehav. Neurol. 2019, 32, 87–94. [Google Scholar] [CrossRef]
- Craig, F.; Operto, F.F.; De Giacomo, A.; Margari, L.; Frolli, A.; Conson, M.; Ivagnes, S.; Monaco, M.; Margari, F. Parenting stress among parents of children with Neurodevelopmental Disorders. Psychiatry Res. 2016, 242, 121–129. [Google Scholar] [CrossRef] [PubMed]
- Operto, F.F.; Mazza, R.; Pastorino, G.M.G.; Campanozzi, S.; Verrotti, A.; Coppola, G. Parental stress in a sample of children with epilepsy. Acta Neurol. Scand. 2019, 140, 87–92. [Google Scholar] [CrossRef] [PubMed]
- Operto, F.F.; Mazza, R.; Pastorino, G.M.G.; Campanozzi, S.; Margari, L.; Coppola, G. Parental stress in pediatric epilepsy after therapy withdrawal. Epilepsy Behav. 2019, 94, 239–242. [Google Scholar] [CrossRef] [PubMed]
- Operto, F.F.; Pastorino, G.M.G.; Pippa, F.; Padovano, C.; Vivenzio, V.; Scuoppo, C.; Pistola, I.; Coppola, G. Psychiatric Symptoms and Parental Stress in Children and Adolescents with Epilepsy. Front. Neurol. 2021, 12, 778410. [Google Scholar] [CrossRef]
- Smirni, D.; Carotenuto, M.; Precenzano, F.; Smirni, P.; Operto, F.F.; Marotta, R.; Roccella, M. Memory performances and personality traits in mothers of children with obstructive sleep apnea syndrome. Psychol. Res. Behav. Manag. 2019, 12, 481–487. [Google Scholar] [CrossRef] [Green Version]
- Tong, X.; Deng, Y.; Liu, L.; Tang, X.; Yu, T.; Gan, J.; Cai, Q.; Luo, R.; Xiao, N. Clinical implementation of ketogenic diet in children with drug-resistant epilepsy: Advantages, disadvantages, and difficulties. Seizure 2022, 99, 75–81. [Google Scholar] [CrossRef]
- Bruce, S.; Devlin, A.; Air, L.; Cook, L. Changes in quality of life as a result of ketogenic diet therapy: A new approach to assessment with the potential for positive therapeutic effects. Epilepsy Behav. 2017, 66, 100–104. [Google Scholar] [CrossRef]
- Barwick, K.; Parker, T.; Murphy, N.; Todd, A.; Leveritt, M.; Wilkinson, S.A. Development and pilot testing of a parent-reported health-related quality of life measure for children on the ketogenic diet: The KetoQoL. Nutr. Diet. 2017, 74, 521–528. [Google Scholar] [CrossRef]
- Wanigasinghe, J.; Jayawickrama, A.; Hewawitharana, G.; Munasinghe, J.; Weeraratne, C.T.; Ratnayake, P.; Wijesekara, D.S.; Fernando, S.; Rupasinghe, P. Experience during COVID-19 lockdown and self-managing strategies among caregivers of children with epilepsy: A study from low middle income country. Seizure 2021, 84, 112–115. [Google Scholar] [CrossRef]
- Cesario, S.; Basile, C.; Trevisan, M.; Gigliotti, F.; Manti, F.; Esposito, R.M.; Abbracciavento, G.; Mastrangelo, M. Loss of Continuity of Care in Pediatric Neurology Services during COVID-19 Lockdown: An Additional Stressor for Parents. Children 2022, 9, 867. [Google Scholar] [CrossRef]
- Werling, A.M.; Walitza, S.; Eliez, S.; Drechsler, R. Impact of the COVID-19 pandemic on mental health and family situation of clinically referred children and adolescents in Switzerland: Results of a survey among mental health care professionals after 1 year of COVID-19. J. Neural. Transm. 2022, 129, 675–688. [Google Scholar] [CrossRef] [PubMed]
- Operto, F.F.; Coppola, G.; Vivenzio, V.; Scuoppo, C.; Padovano, C.; de Simone, V.; Rinaldi, R.; Belfiore, G.; Sica, G.; Morcaldi, L.; et al. Impact of COVID-19 Pandemic on Children and Adolescents with Neuropsychiatric Disorders: Emotional/Behavioral Symptoms and Parental Stress. Int. J. Environ. Res. Public Health 2022, 19, 3795. [Google Scholar] [CrossRef] [PubMed]
- Operto, F.F.; Scaffidi Abbate, C.; Piscitelli, F.T.; Olivieri, M.; Rizzo, L.; Sica, G.; Labate, A.; Roccella, M.; Carotenuto, M.; Pastorino, G.M.G. Adolescents with Neuropsychiatric Disorders during the COVID-19 Pandemic: Focus on Emotional Well-Being and Parental Stress. Healthcare 2022, 10, 2368. [Google Scholar] [CrossRef]
- Armeno, M.; Caballero, E.; Verini, A.; Reyes, G.; Galarza, N.; Cresta, A.; Caraballo, R.H. Telemedicine- versus outpatient-based initiation and management of ketogenic diet therapy in children with drug-resistant epilepsy during the COVID-19 pandemic. Seizure 2022, 98, 37–43. [Google Scholar] [CrossRef] [PubMed]
Sex (Male:Female) | 20:16 |
---|---|
Mean Age at the Diet Onset | 6.84 ± 2.17 |
Diagnosis | |
Generalized epileptic encephalopathies | 17 (47%) |
Focal symptomatic epilepsy | 4 (11%) |
West syndrome | 2 (6%) |
Dravet syndrome | 3 (8%) |
Lennox–Gastaut syndrome | 4 (11%) |
Angelman syndrome | 1 (3%) |
Tuberous sclerosis complex | 5 (14%) |
Psychomotor Delay/Intellectual Disability | |
Mild to moderate | 15 (42%) |
Severe | 16 (44%) |
Profound | 5 (14%) |
Cerebral Palsy | |
Tetraparesis–diplegia | 16 (44%) |
Hemiparesis | 1 (3%) |
Hypotonic syndrome | 2 (6%) |
MRI Findings | |
Tubers | 5 (14%) |
Neuronal migration disorder | 4 (11%) |
Hypoxic–ischemic damage | 16 (44%) |
Aspecific or normal | 7 (19%) |
Patient Number | Sex | Age * | Seizure Onset * | Epilepsy Duration * | Diagnosis | Aetiology | Seizure Frequency | ASMs | Type of Ketogenic Diet | Response to the KD (Seizure Reduction % after 12 Months) |
---|---|---|---|---|---|---|---|---|---|---|
1 | M | 10.5 | 1.5 | 9 | GE | symptomatic | D | VPA, LTG | 4:1 | >50 |
2 | F | 8.5 | 2 | 6.5 | GE | symptomatic | D | PB, VPA, LTG | 4:1 | >50 |
3 | M | 5.5 | 2 | 3.5 | GE | unknown | MD | VPA, LTG, ETS | 4:1 | <50 |
4 | F | 4 | 3 | 1 | TSC | genetic | MD | CBZ, LTG, CLB | 4:1 | 100 |
5 | F | 8.8 | 3.5 | 5.3 | TSC | genetic | W | CBZ, VGB, CLB | 4:1 | >50 |
6 | M | 8 | 2.5 | 5.5 | GE | symptomatic | D | VPA, LTG | 4:1 | >50 |
7 | M | 2.5 | 0.5 | 2 | West | unknown | D | VPA, VGB | 4:1 | <50 |
8 | F | 6.5 | 3 | 3.5 | LGS | symptomatic | MD | CBZ, TPM, CLO | 4:1 | <50 |
9 | M | 7.7 | 1.5 | 6.2 | GE | symptomatic | MD | VPA, LTG, PB | 4:1 | >50 |
1F | F | 4 | 2 | 2 | LGS | symptomatic | MD | FLB, VPA, LTG | 4:1 | >50 |
11 | F | 9.5 | 1.5 | 8 | GE | symptomatic | D | VPA, LTG | 4:1 | >50 |
12 | M | 9 | 2.5 | 6.5 | GE | unknown | D | PB, VPA, LTG | 4:1 | >50 |
13 | M | 5.5 | 2 | 3.5 | TSC | genetic | D | CBZ, LTG, CLB | 4:1 | 100 |
14 | F | 6.5 | 3.5 | 3 | TSC | genetic | W | VPA, VGB, CLO | 4:1 | >50 |
15 | M | 7 | 2.5 | 4.5 | FSG | symptomatic | D | VPA, LTG, CLB | 4:1 | >50 |
16 | F | 9.5 | 1.5 | 8 | GE | symptomatic | D | LEV, PB | 4:1 | <50 |
17 | F | 7.5 | 2 | 5.5 | GE | symptomatic | MD | VPA, LTG | 4:1 | >50 |
18 | F | 6 | 0.5 | 5.5 | GE | symptomatic | MD | LEV, VPA | 4:1 | 100 |
19 | M | 6.6 | 1.5 | 5.1 | LGS | symptomatic | MD | VPA, LTG, CLB | 4:1 | >50 |
2F | F | 3 | 0.5 | 2.5 | LGS | unknown | MD | VPA, CLB | 4:1 | >50 |
21 | M | 7.5 | 1.5 | 6 | GE | symptomatic | W | VPA, LTG, ETS | 4:1 | <50 |
22 | F | 9.5 | 2.5 | 7 | GE | symptomatic | D | LEV, PB | 4:1 | >50 |
23 | M | 7 | 1.5 | 5.5 | Angelman | genetic | D | VPA, ETS, CLZ | 4:1 | >50 |
24 | F | 8.5 | 2 | 6.5 | FSG | symptomatic | W | LCS, LEV, CLB | 4:1 | >50 |
25 | M | 6 | 1 | 5 | Dravet | genetic | MD | VPA, STR, CLB | 4:1 | >50 |
26 | F | 6.5 | 1.5 | 5 | GE | symptomatic | MD | VPA, LTG | 4:1 | <50 |
27 | M | 9.5 | 1 | 8.5 | Dravet | genetic | MD | STP, LTG, CLB | 4:1 | <50 |
28 | M | 6 | 0.5 | 5.5 | Dravet | genetic | MD | VPA, STP, CLB | 4:1 | >50 |
29 | M | 10 | 2 | 8 | GE | unknown | MD | VPA, PB, LTG | 4:1 | >50 |
3F | M | 5.5 | 1.5 | 4 | FSG | symptomatic | MD | LCS, LEV, CLO | 4:1 | 100 |
31 | M | 4 | 2.5 | 1.5 | TSC | genetic | W | CBZ, VGB, CLB | 4:1 | >50 |
32 | M | 10 | 3.5 | 6.5 | FSG | symptomatic | W | LCS, LEV, CLB | 4:1 | >50 |
33 | F | 4.5 | 2.5 | 2 | GE | symptomatic | D | PB, TPM, CLB | 4:1 | >50 |
34 | M | 6.5 | 3.5 | 3 | GE | symptomatic | D | VPA, VGB, CLB | 4:1 | <50 |
35 | F | 6 | 2,5 | 3.5 | GE | unknown | D | VPA, LTG, CLB | 4:1 | 100 |
36 | M | 3 | 0.5 | 2.5 | West | symptomatic | D | VGB, VPA | 4:1 | >50 |
mean ± SD | 6.84 ± 2.17 | 1.93 ± 0.90 | 4.91 ± 2.12 |
Total Patients with at Least One Early or Late Adverse Event on Ketogenic Diet = 23 (64%) | |
---|---|
Early | Late |
Constipation = 17 (47%) | Weight Loss = 7 (19%) |
Drowsiness/lethargy = 10 (28%) | Vomiting = 3 (8%) |
Lack of appetite/food refusal = 9 (25%) | Gastroesophageal reflux = 1 (3%) |
Nausea/vomiting = 9 (25%) | |
Diarrhea = 7 (19%) | |
Abdominal pain = 4 (11%) | |
Irritability = 3 (8%) | |
Dehydration = 2 (6%) | |
Adverse events are often combined in the same patient. |
Parenting Stress Index (PSI) | ||||
---|---|---|---|---|
Baseline (Mean ± SD) n = 36 | 6 Months (Mean ± SD) n = 31 | 12 Months (Mean ± SD) n = 28 | Statistical | |
Parental Distress (PD) | 90.41 ± 7.31 | 92.58 ± 5.30 | 94.64 ± 5.26 | F = 7.373 p = 0.025 |
Parent–Child Dysfunctional Interaction (P-CDI) | 89.58 ± 9.05 | 92.58 ± 5.61 | 93.04 ± 5.50 | F = 1.000 p = 0.607 |
Difficult Child (DC) | 89.86 ± 8.90 | 90.97 ± 9.35 | 90.71 ± 7.66 | F = 0.269 p = 0.269 |
Total Stress (TS) | 90.83 ± 7.32 | 93.39 ± 5.23 | 95.54 ± 4.58 | F = 6.735 p = 0.034 |
T0 vs. T1 | T1 vs. T2 | T0 vs. T2 | |
---|---|---|---|
Parental Distress (PD) | W = 1.084 p = 0.278 | W = 2.588 p = 0.010 | W = 2.316 p = 0.021 |
Total Stress (TS) | W = 1.071 p = 0.091 | W = 2.652 p = 0.008 | W = 2.735 p = 0.006 |
difficulties in management | 26 (72%) |
lack of time | 23 (64%) |
child compliance | 20 (55%) |
adverse events | 15 (42%) |
cost | 8 (22%) |
social/outing restrictions | 7 (19%) |
none | 6 (17%) |
lack of clinical support | 3 (8%) |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Operto, F.F.; Labate, A.; Aiello, S.; Perillo, C.; de Simone, V.; Rinaldi, R.; Coppola, G.; Pastorino, G.M.G. The Ketogenic Diet in Children with Epilepsy: A Focus on Parental Stress and Family Compliance. Nutrients 2023, 15, 1058. https://doi.org/10.3390/nu15041058
Operto FF, Labate A, Aiello S, Perillo C, de Simone V, Rinaldi R, Coppola G, Pastorino GMG. The Ketogenic Diet in Children with Epilepsy: A Focus on Parental Stress and Family Compliance. Nutrients. 2023; 15(4):1058. https://doi.org/10.3390/nu15041058
Chicago/Turabian StyleOperto, Francesca Felicia, Angelo Labate, Salvatore Aiello, Cristina Perillo, Valeria de Simone, Rosetta Rinaldi, Giangennaro Coppola, and Grazia Maria Giovanna Pastorino. 2023. "The Ketogenic Diet in Children with Epilepsy: A Focus on Parental Stress and Family Compliance" Nutrients 15, no. 4: 1058. https://doi.org/10.3390/nu15041058
APA StyleOperto, F. F., Labate, A., Aiello, S., Perillo, C., de Simone, V., Rinaldi, R., Coppola, G., & Pastorino, G. M. G. (2023). The Ketogenic Diet in Children with Epilepsy: A Focus on Parental Stress and Family Compliance. Nutrients, 15(4), 1058. https://doi.org/10.3390/nu15041058